Table 2 Baseline clinicopathologic characteristics of patients with second-line treatment
From: Right- and left-sided colorectal cancers respond differently to cetuximab
Clinicopathologic characteristic | Â | Cetuximab group | Â | Chemotherapy alone group | P valuec | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | All patients | RSCC | LSCRC | P value | Â | All patients | RSCC | LSCRC | P value | |
No. of patients |  | 96 | 28 | 68 | — |  | 93 | 44 | 49 | — | 0.011* |
Median age at diagnosis | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
    ≤65 years |  | 82 (85.4) | 21 (75.0) | 61 (89.7) | 0.108 |  | 72 (77.4) | 30 (68.2) | 42 (85.7) | 0.051 | 0.191 |
    >65 years |  | 14 (14.6) | 7 (25.0) | 7 (10.3) |  |  | 21 (22.6) | 14 (31.8) | 7 (14.3) |  |  |
Sex | Â | Â | Â | Â | 0.488 | Â | Â | Â | Â | 1.000 | 0.105 |
    Male |  | 63 (65.6) | 20 (71.4) | 43 (63.2) |  |  | 50 (53.8) | 24 (54.5) | 26 (53.1) |  |  |
    Female |  | 33 (34.4) | 8 (28.6) | 25 (36.8) |  |  | 43 (46.2) | 20 (45.5) | 23 (46.9) |  |  |
ECOG performance status | Â | Â | Â | Â | 0.074 | Â | Â | Â | Â | 0.438 | 0.310 |
    0 |  | 53 (55.2) | 13 (46.4) | 40 (58.8) |  |  | 41 (44.0) | 19 (43.2) | 22 (44.9) |  |  |
    1 |  | 35 (36.5) | 11 (39.3) | 24 (35.3) |  |  | 42 (45.2) | 22 (50.0) | 20 (40.8) |  |  |
    ≥2 |  | 8 (8.3) | 4 (14.3) | 4 (5.9) |  |  | 10 (10.8) | 3 (6.8) | 7 (14.3) |  |  |
Pathology | Â | Â | Â | Â | 0.102 | Â | Â | Â | Â | 0.183 | 0.822 |
    Adenocarcinoma |  | 84 (87.5) | 22 (78.6) | 62 (91.2) |  |  | 83 (89.2) | 37 (84.1) | 46 (93.9) |  |  |
    Mucinous & signet-ring cell |  | 12 (12.5) | 6 (21.4) | 6 (8.8) |  |  | 10 (10.8) | 7 (15.9) | 3 (6.1) |  |  |
Metastasis | Â | Â | Â | Â | 0.804 | Â | Â | Â | Â | 1.000 | 0.005* |
    Single |  | 69 (71.9) | 21 (75.0) | 48 (70.6) |  |  | 48 (51.6) | 23 (52.3) | 25 (51.0) |  |  |
    Multiple |  | 27 (28.1) | 7 (25.0) | 20 (29.4) |  |  | 45 (48.4) | 21 (47.7) | 24 (49.0) |  |  |
Metastasis resection | Â | 24 (25.0) | 6 (21.4) | 18 (26.5) | 0.796 | Â | 16 (17.2) | 11 (25.0) | 15 (30.6) | 0.646 | 0.215 |
Total cycles of cetuximab (median) |  | 5 (2-20) | 4 (2-13) | 5 (2-20) | 0.272 |  | — | — | — | — | — |
Total cycles of chemotherapy (median) | Â | 8 (2-66) | 7 (4-35) | 8 (2-66) | 0.548 | Â | 6 (2-36) | 6 (2-36) | 6 (2-27) | 1.000 | 0.031* |
All three active drugsa | Â | 87 (90.6) | 24 (85.7) | 63 (92.6) | 0.441 | Â | 84 (90.3) | 39 (88.6) | 45 (91.8) | 0.731 | 1.000 |
Backbone chemotherapy | Â | Â | Â | Â | 0.139 | Â | Â | Â | Â | 1.000 | 0.745 |
    Oxaliplatin-based |  | 27 (28.1) | 11 (39.3) | 16 (23.5) |  |  | 24 (25.8) | 11 (25.0) | 13 (26.5) |  |  |
    Irinotecan-based |  | 69 (71.9) | 17 (60.7) | 52 (76.5) |  |  | 69 (74.2) | 33 (75.0) | 36 (73.5) |  |  |
Bevacizumab during the disease | Â | 27 (28.1) | 11 (39.3) | 16 (23.5) | 0.637 | Â | 22 (23.7) | 8 (18.2) | 14 (28.6) | 0.329 | 0.510 |
Recurrent diseaseb | Â | 42 (43.8) | 6 (21.4) | 36 (52.9) | 0.006* | Â | 33 (35.5) | 19 (43.2) | 14 (28.6) | 0.199 | 0.298 |